Publications by authors named "David B Rawlins"

Claim this Profile
T
The Spanish pathway program: Introducing, recruiting, and retaining Spanish-speaking students to the pharmacy profession.
Angela Chu, Trang Susan Nguyen, David B Rawlins

Curr Pharm Teach Learn· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demonstration of Smartphones as Viable Tools for Adolescent Substance Use Surveillance.
Krystal K Riccio, David B Rawlins, Jeffery N Talbot, Carol J Boyd

Subst Use Misuse· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biopharmaceutical Characterization and Oral Efficacy of a New Rapid Acting Antidepressant Ro 25-6981.
Venkata K Yellepeddi, Maryia Y Zhudeva, Fereshteh Movahedi, Annh Vo, Julie Phan, David B Rawlins

J Pharm Sci· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice.
David R Powell, Melinda G Smith, Deon D Doree, Angela L Harris, Jennifer Greer, David B Rawlins

J Pharmacol Exp Ther· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes.
Nicole C Goodwin, Zhi-Ming Ding, Bryce A Harrison, Eric D Strobel, Angela L Harris, David B Rawlins

J Med Chem· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent.
Raj N Misra, Hai-yun Xiao, Kyoung S Kim, Songfeng Lu, Wen-Ching Han, David B Rawlins

J Med Chem· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2.
David R Powell, Melinda G Smith, Deon D Doree, Angela L Harris, Wendy W Xiong, David B Rawlins

Pharmacol Res Perspect· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.
Nicole C Goodwin, Giovanni Cianchetta, Hugh A Burgoon, Jason Healy, Ross Mabon, David B Rawlins

ACS Med Chem Lett· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.
Bryce A Harrison, Zheng Y Almstead, Hugh Burgoon, Michael Gardyan, Nicole C Goodwin, David B Rawlins

ACS Med Chem Lett· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reaction profiling by ultra high-pressure liquid chromatography/time-of-flight mass spectrometry in support of the synthesis of DNA-encoded libraries.
Leonard O Hargiss, G Greg Zipp, Theodore C Jessop, Xuejun Sun, Philip Keyes, David B Rawlins

J Chromatogr B Analyt Technol Biomed Life Sci· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma.
Bryce A Harrison, N Andrew Whitlock, Michael V Voronkov, Zheng Y Almstead, Kun-jian Gu, David B Rawlins

J Med Chem· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Nicole C Goodwin, Ross Mabon, Bryce A Harrison, Melanie K Shadoan, Zheng Y Almstead, David B Rawlins

J Med Chem· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent.
Raj N Misra, Hai-yun Xiao, Kyoung S Kim, Songfeng Lu, Wen-Ching Han, David B Rawlins

J Med Chem· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analogues.
Raj N Misra, Hai yun Xiao, David B Rawlins, Weifang Shan, Kristen A Kellar

Bioorg Med Chem Lett· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases.
Raj N Misra, David B Rawlins, Hai-yun Xiao, Weifang Shan, Isia Bursuker

Bioorg Med Chem Lett· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.
Kyoung Soon Kim, S David Kimball, Raj N Misra, David B Rawlins, John T Hunt

J Med Chem· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Pinene Path to Taxanes. 4. Approaches to Taxol and Taxol Analogs through Elaboration of Aromatic C-Ring Precursors.
Paul A. Wender, Timothy E. Glass, Nancy E. Krauss, Michel Mühlebach, Bernd Peschke, David B. Rawlins

J Org Chem· November 1996

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis